 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...2223242526272829303132...7475» |
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors. (Pubmed Central) - Jun 24, 2021
Ranibizumab and aflibercept presented similar anatomical and functional outcomes in 18-month follow-up in patients with DME. It is important to determine factors, affecting VA, so as to provide individualized treatment.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Management of stage 3B Coats disease: presentation of a combined treatment modality and long-term follow-up. (Pubmed Central) - Jun 23, 2021
It is important to determine factors, affecting VA, so as to provide individualized treatment. The combined treatment modality presented in this study is an effective way in the management of stage 3B Coats disease with total ERD.
- | Lucentis (ranibizumab) / Roche, Novartis
Preclinical, Journal: Laser-induced choroidal neovascularization: A case report and some reflection on animal models for age-related macular degeneration. (Pubmed Central) - Jun 23, 2021
For young patients with laser induced CNV, intravitreal anti-VEGF injections may be helpful in visual improvement and CNV regression. Moreover, age seems to be a significant factor thus we propose that old animals may be more appropriate for laser induced CNV animal models of age-related macular degeneration.
- || Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: Quantification of anterior chamber reaction after intravitreal injections of conbercept and ranibizumab: a pilot study. (Pubmed Central) - Jun 22, 2021
Moreover, age seems to be a significant factor thus we propose that old animals may be more appropriate for laser induced CNV animal models of age-related macular degeneration. No abstract available
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Retrospective data, Journal: Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data. (Pubmed Central) - Jun 22, 2021
No abstract available Macular oedema exposure over the first 52 weeks of ranibizumab treatment is a negative prognostic factor for long-term visual acuity improvement in centre-involved DMO.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Real-world evidence: REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY: Twelve-Month Results From the LUMINOUS Study. (Pubmed Central) - Jun 22, 2021
Macular oedema exposure over the first 52 weeks of ranibizumab treatment is a negative prognostic factor for long-term visual acuity improvement in centre-involved DMO. LUMINOUS confirms the effectiveness and safety of ranibizumab in treatment-naive patients with PCV.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: EVALUATION OF SURGICAL FACTORS AFFECTING VITREOUS HEMORRHAGE FOLLOWING PORT DELIVERY SYSTEM WITH RANIBIZUMAB IMPLANT INSERTION IN A MINIPIG MODEL. (Pubmed Central) - Jun 22, 2021
LUMINOUS confirms the effectiveness and safety of ranibizumab in treatment-naive patients with PCV. In this minipig surgical model of VH, scleral dissection followed by pars plana laser ablation before pars plana incision most effectively mitigated VH secondary to PDS implant insertion.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Recognizing the True Cost of Medical Spending-an Assessment of Ranibizumab for Retinal Disorders. (Pubmed Central) - Jun 22, 2021
In this minipig surgical model of VH, scleral dissection followed by pars plana laser ablation before pars plana incision most effectively mitigated VH secondary to PDS implant insertion. No abstract available
- | Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Journal: The impact of the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) Study in Australia. (Pubmed Central) - Jun 22, 2021
No abstract available No abstract available
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration. (Pubmed Central) - Jun 22, 2021
Regular monitoring and anti-VEGF treatment over 10 years reduce the risk of visual loss of 15 letters or more in patients with neovascular AMD. The most common cause of substantial visual decline was macular atrophy.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, P1/2 data, Journal: Phase I/II randomized study of proton beam with anti-VEGF for exudative age-related macular degeneration: long-term results. (Pubmed Central) - Jun 22, 2021
Radiation retinopathy risk was low and does not appear visually significant. Long-term vision was limited by GA development especially in the 24 GyE group.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Risk of stroke associated with intravitreal ranibizumab injections in age-related macular degeneration: a nationwide case-crossover study. (Pubmed Central) - Jun 22, 2021
A secondary analysis indicated the possibility of an increased risk of hemorrhagic stroke, with borderline significance. Further research is needed regarding the underlying biological mechanisms and drug safety.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Association between the patterns of diabetic macular edema and photoreceptors' response after intravitreal ranibizumab treatment: a spectral-domain optical coherence tomography study. (Pubmed Central) - Jun 22, 2021
Patients with DME presented significant photoreceptors' restoration after intravitreal ranibizumab injections at the 12-month follow-up. The improvement in EZ defect size and IZ was dependent on the pattern of DME on SD-OCT.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Journal: Long-term resolution of chronic macular edema after a single dose of intravitreal dexamethasone in familial retinal arterial macroaneurysm. (Pubmed Central) - Jun 22, 2021
Intravitreal dexamethasone implantation in the right eye, on the other hand, resulted in marked visual and structural improvement. Intravitreal dexamethasone injections have beneficial anatomical and visual outcomes in FRAM patients with persistent macular edema poorly responsive to intravitreal injections.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Immediate changes in blood pressure during intravitreal anti-VEGF agents' applications in exudative age-related macular degeneration patients. (Pubmed Central) - Jun 22, 2021
Our study results show that intravitreal anti-VEGF injection is associated with a short-term increase in SABP. To prevent potential systemic complications during anti-VEGF administration, the systemic status of patients with ARMD should be evaluated before the injection and those with a risk of high SABP during injection should be closely monitored.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Oliver McFarlane syndrome and choroidal neovascularisation: a case report. (Pubmed Central) - Jun 22, 2021
To prevent potential systemic complications during anti-VEGF administration, the systemic status of patients with ARMD should be evaluated before the injection and those with a risk of high SABP during injection should be closely monitored. We report the first case of CNV secondary to OMS and its successful treatment with intravitreal anti-vascular endothelial growth factor injections.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Ocular microcirculation changes, measured with laser speckle flowgraphy and optical coherence tomography angiography, in branch retinal vein occlusion with macular edema treated by ranibizumab. (Pubmed Central) - Jun 22, 2021
We report the first case of CNV secondary to OMS and its successful treatment with intravitreal anti-vascular endothelial growth factor injections. ONH blood flow may be a pre-IVR biomarker of both visual outcomes and post-IVR deep macular microcirculation in eyes with BRVOME.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Long-term stability of anti-vascular endothelial cell growth factor (a-VGEF) biologics under physiologically relevant conditions and its impact on the development of long-acting delivery systems. (Pubmed Central) - Jun 22, 2021
Even though the aggregated forms of bevacizumab and aflibercept bind to VEGF, the consequences of aggregation on immunogenicity, implant function and efficacy are unknown. These results highlight the importance of maintaining long-term drug stability under physiologically relevant conditions which is necessary for achieving efficacy with an in vivo continuous drug delivery device such as the PDS implant.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: Intravitreal anti-vascular endothelial growth factor medications during pregnancy: current perspective. (Pubmed Central) - Jun 22, 2021
A timely obstetrics consultation may help in this situation. Attempt for pregnancy should be withheld for at least 3 months following last injection of ranibizumab and aflibercept, and for at least 6 months following last injection of bevacizumab.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Mingjing granule, a traditional Chinese medicine in the treatment of neovascular age-related macular degeneration: study protocol for a randomized controlled trial. (Pubmed Central) - Jun 22, 2021
Attempt for pregnancy should be withheld for at least 3 months following last injection of ranibizumab and aflibercept, and for at least 6 months following last injection of bevacizumab. Based on previous empirical and animal laboratory studies, this study will address the question of whether Mingjing granule could contribute to improving efficacy, safety, and efficiency with need for fewer intravitreal injections of anti-VEGF, improving compliance and visual outcomes in the management of persons with nAMD.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Comparison of the effects of anti-vascular endothelial growth factor treatments on pigment epithelial detachment in age-related macular degeneration. (Pubmed Central) - Jun 22, 2021
Although the maximum improvement was seen at third month, final visual acuity and parameters of PED were better in aflibercept group. The efficacy of the both drug to choroidal neovascularization was known; however, in cases with significant PED, aflibercept can be consider for the first-level treatment.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Long-term full-field and multifocal electroretinographic changes after treatment with ranibizumab in patients with diabetic macular edema. (Pubmed Central) - Jun 22, 2021
This improvement was significant at months 9 and 12. A significant improvement in ff-ERG was observed at month 12.
- | Triesence (triamcinolone acetonide injectable suspension) / Novartis, Lucentis (ranibizumab) / Roche, Novartis
Journal: Evaluation of vitrectomy combined preoperative intravitreal ranibizumab and postoperative intravitreal triamcinolone acetonide for proliferative diabetic retinopathy. (Pubmed Central) - Jun 22, 2021
A significant improvement in ff-ERG was observed at month 12. In patients undergoing PPV for PDR, preoperative IVR significantly reduced the occurrence of intraoperative and postoperative complications, and the combination of preoperative IVR and postoperative IVTA can better improve the postoperative visual outcome.
- || Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: An efficacy comparison of combination of different anti-vascular endothelial growth factors and photodynamic therapy in patients with pachychoroid neovasculopathy. (Pubmed Central) - Jun 22, 2021
Anti-VEGF agents with full-dose PDT were well tolerated for the first 3 months and were highly effective treatment option in order to naive PNV patients. However, in long-term follow-ups, the effectiveness of IVA was superior to other anti-VEGFs.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Retrospective data, Journal: Incidence of endophthalmitis following intravitreal anti VEGF injections at a tertiary care hospital in Pakistan. (Pubmed Central) - Jun 22, 2021
However, in long-term follow-ups, the effectiveness of IVA was superior to other anti-VEGFs. The institutional procedure protocol was found to be effective as the rate of infectious endophthalmitis was lower than what is reported in literature.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical: Comparison of Two Different Intravitreal Injection Techniques. (Pubmed Central) - Jun 22, 2021
P=N/A
The IIG appears to significantly reduce procedure time, be associated with a lower incidence of subconjunctival hemorrhage and engender better patient acceptance. ClinicalTrials.gov (NCT04455399).
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Intravitreally injected ranibizumab versus photodynamic therapy for CNV secondary to choroidal osteoma: a 7-year follow-up case report. (Pubmed Central) - Jun 22, 2021
ClinicalTrials.gov (NCT04455399). No abstract available
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Cardiovascular risk in patients receiving ranibizumab for exudative age-related macular degeneration: a nationwide self-controlled case-series study. (Pubmed Central) - Jun 16, 2021
Ranibizumab intravitreal injections did not increase the overall risk of stroke or AMI. Although the cardiovascular risk in patient receiving ranibizumab seems to be low, continuous monthly use of ranibizumab for high-risk patients should be judged carefully.
- ||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion date, Trial primary completion date: RainbowExt: Rainbow Extension Study (clinicaltrials.gov) - Jun 15, 2021
P3, N=180, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Although the cardiovascular risk in patient receiving ranibizumab seems to be low, continuous monthly use of ranibizumab for high-risk patients should be judged carefully. Trial completion date: Oct 2022 --> May 2022 | Trial primary completion date: Oct 2022 --> May 2022
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, HEOR, Real-world evidence: ETOILE: Real-World Evidence of 24 Months of Ranibizumab 0.5 mg in Patients with Visual Impairment Due to Diabetic Macular Edema. (Pubmed Central) - Jun 12, 2021
BCVA variation of ≥6 letters by M3 was predictive of BCVA gains at M24 (p=0.007), as was hypertension medication at baseline (p=0.022). Real-world ranibizumab treatment improved VA in DME patients, despite fewer injections than recommended.
- |||| 601A / 3SBio
New P2 trial: 601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV) (clinicaltrials.gov) - Jun 10, 2021
P2, N=60, Recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
...or repurposed Avastin, create a new patent and rebrand it as Lucentis (etc) and charge a boatload more?? (Twitter) - Jun 9, 2021
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Long-term switching between ranibizumab and aflibercept in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. (Pubmed Central) - Jun 9, 2021
Although the timings of switching were similar, switching rate was higher in patients undergoing ranibizumab therapy than in those undergoing aflibercept therapy. The switching rate was especially higher in PCV patients undergoing ranibizumab therapy.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Journal: Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration. (Pubmed Central) - Jun 9, 2021
This may be explained by drug tolerance to aflibercept. Our findings may facilitate making appropriate treatment decisions, potentially improving patient outcomes.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Journal: INVICTUS: Intravitreal anti-VEGF and dexamethasone implant comparison for the treatment of diabetic macular edema: A 12 months follow-up study. (Pubmed Central) - Jun 8, 2021
CRT decreased by 124.4 µm at M6 and 99.3 µm at M12 in RAN group, 144.3 µm and 101.5 µm in AFL group and finally 95.6 µm and 162.7 µm in DXI group. In summary, these three drugs provide an efficient treatment option with an acceptable benefit-risk ratio for the treatment of naive patients with DME, whether on BCVA or CRT on the first year of treatment.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Secondary choroidal neovascularization due to choroidal osteoma after 9 years follow-up. (Pubmed Central) - Jun 8, 2021
Optical coherence tomography angiography combined with FFA and ICGA is used to analysis the characteristics of secondary choroidal neovascularization. Optical coherence tomography angiography can reveal some unique characteristics in the vascular changes compared to fundus fluorescein angiography.
- || CMAB818 (ranibizumab biosimilar) / 3SBio
Enrollment open: Phase I Study to Compare CMAB818 Injection and Lucentis (clinicaltrials.gov) - Jun 8, 2021
P1, N=24, Recruiting, Sponsor: Shanghai Biomabs Pharmaceutical Co., Ltd.
Optical coherence tomography angiography can reveal some unique characteristics in the vascular changes compared to fundus fluorescein angiography. Not yet recruiting --> Recruiting
- || Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab. (Pubmed Central) - Jun 5, 2021
Switching to aflibercept from bevacizumab or ranibizumab in eyes with persistent macular oedema due to RVO can lead to functional and anatomical improvement. This effect was more obvious in eyes with a greater CMT prior to the switch.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Journal: Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion. (Pubmed Central) - Jun 5, 2021
These real world data demonstrate more modest clinical improvements from anti-vascular endothelial growth factor treatment than reported in clinical trials. The functional outcomes of ranibizumab and aflibercept in both treatment naïve and refractory cases were equivocal while the anatomical outcomes of aflibercept may be superior.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Macular atrophy development in neovascular age-related macular degeneration during first year of treatment: Incidence and risk factors. (Pubmed Central) - Jun 5, 2021
To assess the development of macular atrophy, according to the new Classification of Atrophy Meetings criteria, in patients with treatment-naïve neovascular age-related macular degeneration during the first year of treatment with ranibizumab or aflibercept, and to determine baseline factors predictive of atrophy development...Predictors of atrophy development have the potential to change treatment practices. Further research is warranted.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Intraocular Pressure Changes after Intravitreal Bevacizumab or Ranibizumab Injection: A Retrospective Study. (Pubmed Central) - Jun 5, 2021
Incidence of delayed and sustained OHT is low after a single or multiple intravitreal bevacizumab and ranibizumab injections. Clinicians should be aware of possibility of OHT or glaucoma after the procedure.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Results of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Inflammatory Choroidal Neovascularization. (Pubmed Central) - Jun 5, 2021
CNV is a sight-threatening complication of uveitis. IVT anti-VEGF seems to be an effective and safe treatment for iCNV when inflammation is controlled.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Juxtapapillary neovascular membrane associated with optic nerve drusen. (Pubmed Central) - Jun 4, 2021
Although optic nerve head drusen are considered benign, neovascular membranes can be a complication. Anti-VEGFs are an effective alternative for treatment.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Changes in Macular Microvascular Structure in Macular Edema Secondary to Branch Retinal Vein Occlusion Treated with Antivascular Endothelial Growth Factor for One Year. (Pubmed Central) - Jun 1, 2021
The PERIM and AI at 12 months were significantly associated with the recurrence of macular edema, and the changes in vascular density in the SCP and PERIM were significantly associated with the number of injections within 12 months (P < 0.05). One year after ranibizumab treatment, the area and perimeter of the FAZ were enlarged, while the VD of the SCP and DCP remained stable, which indicated that ranibizumab treatment did not improve macular blood supply and macular ischemia in BRVO patients.
- || Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Retrospective data, Review, Journal: Intravitreal conbercept improves outcome in patients undergoing vitrectomy for proliferative diabetic retinopathy: A systematic review and meta-analysis. (Pubmed Central) - May 28, 2021
One year after ranibizumab treatment, the area and perimeter of the FAZ were enlarged, while the VD of the SCP and DCP remained stable, which indicated that ranibizumab treatment did not improve macular blood supply and macular ischemia in BRVO patients. Intravitreal conbercept was associated with a more significant BCVA improvement, better intraoperative outcome, and less postoperative vitreous hemorrhage compared to no conbercept.
- || Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: Current intravitreal therapy and ocular hypertension: A review. (Pubmed Central) - May 28, 2021
The studies that reported on short-term IOP elevation (i.e., between 0 and 60 min) showed that an immediate increase in IOP is seen in all patients who receive anti-VEGF agents or triamcinolone acetonide when measured between 0 and 30 min of intravitreal injection and that the IOP elevation decreases over time...Most, if not all, intravitreal agents cause ocular hypertension, both in the short term and long term. The functional consequences of these observations are not very clear.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: VEGF-Independent Activation of Müller Cells by the Vitreous from Proliferative Diabetic Retinopathy Patients. (Pubmed Central) - May 28, 2021
In addition, the FGF receptor tyrosine kinase inhibitor BGJ398, the pan-FGF trap NSC12, the heparin-binding protein antagonist N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe Boc2, and the anti-inflammatory hydrocortisone all inhibited Müller cell activation mediated by PDR vitreous. These findings point to a role for various modulators beside VEGF in Müller cell activation and pave the way to the search for novel therapeutic strategies in PDR.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Significance of monitoring vascular endothelial growth factor, monocyte chemoattractant protein-1 and Interleukin-8 in diabetic macular edema towards early identification of nonresponders to ranibizumab therapy. (Pubmed Central) - May 28, 2021
The cytokines IL-8, MCP-1 were significantly up regulated (P = 0.0048 and 0.029 for MCP-1 and IL-8) in nonresponders. Elevated MCP-1 and IL-8 levels found in the nonresponders could be used as a prognostic marker to identify these groups of patients and can help in developing alternative treatment options along with anti-VEGF therapy.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Microvasculature Changes of Myopic Choroidal Neovascularization and the Predictive Value of Feeder Vessel Disappearance after Ranibizumab Treatment Revealed Using Optical Coherence Tomography Angiography. (Pubmed Central) - May 27, 2021
OCTA allowed the detection of qualitative and quantitative vascular changes in mCNV. The disappearance of the feeder vessel was associated with better anatomical as well as functional outcomes at the last follow-up visit.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Changes in the Ganglion Cell-inner Plexiform Layer after Consecutive Intravitreal Injections of Anti-vascular Endothelial Growth Factor in Age-related Macular Degeneration Patients. (Pubmed Central) - May 27, 2021
The disappearance of the feeder vessel was associated with better anatomical as well as functional outcomes at the last follow-up visit. It has been observed that GCIPL thickness can decrease with only three consecutive anti-VEGF injections as well as with long-term treatment in AMD patients.